BECTON DICKINSON & CO
Known title: 10% OwnerCIK: 0000010795
Associated companies
Transaction History
| BDX | ▼ Sell | Other | 284,771,350 | — | 2/9/2026 | View on chart |
| BDX | ▼ Sell | Other | 57,797,725 | $0 | 4/1/2022 | View on chart |
| BDX | ▼ Sell | Other | 284,771,350 | — | 2/9/2026 | View on chart |
| BDX | ▼ Sell | Other | 57,797,725 | $0 | 4/1/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.